Skip to main content
Download PDF

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE

BMC Nephrology volume 24, Article number: 310 (2023) Cite this article

Abstract

Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full “lay” summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.

Introduction

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors represent a major step in the management of chronic kidney disease (CKD), with evidence from several large randomised clinical trials and collaborative meta-analyses indicating that this medication class reduces progression of kidney disease and kidney failure in a broad range of people with CKD irrespective of diabetes (DM) status, level of kidney function, or primary kidney diagnosis [1,2,3,4]. Furthermore, SGLT-2 inhibition has been shown to improve outcomes in people with diabetes with high cardiovascular risk, and in people with heart failure across the spectrum of left ventricular ejection fraction [4,5,6].

In addition to well-established efficacy, SGLT-2 inhibition has been shown to be safe, with few associated risks, which include mycotic infections, lower limb amputations and ketoacidosis. Importantly, serious side effects are rare, particularly among people without diabetes [4]. A recent meta-analysis assessing the balance of risk and benefit in CKD indicates that the absolute benefits of SGLT-2 inhibition in terms of kidney disease progression, cardiovascular death or hospitalisation for heart failure, and acute kidney injury substantially outweigh any associated risks in the studied populations (Fig. 1) [4].

Fig. 1
figure 1

Absolute benefit and risks of SGLT-2 inhibition for people with CKD with and without diabetes, estimated from 13 large randomised clinical trials of SGLT-2 inhibition (adapted from [4]). CKD – chronic kidney disease. eGFR – estimated glomerular filtration rate. SE – standard error. SGLT-2i – sodium-glucose co-transporter 2 inhibitor. Figure licensed under Creative Commons CC-BY license

Full size image

Given these findings, there is a need to provide practical and pragmatic guidance for the use of this class of medication to facilitate rapid, effective and safe implementation in clinical practice. In 2021, the UK Kidney Association (UKKA) Clinical Practice Guideline: SGLT-2 Inhibition in Adults with Kidney Disease Working Group published a Clinical Practice Guideline on the use of SGLT-2 inhibitors in adults with kidney disease in order to facilitate this, with emphasis on relevant large-scale randomised evidence for the efficacy and safety of SGLT-2 inhibition. This 2023 guideline presents updated Recommendations in light of new evidence from the recent DELIVER and EMPA-KIDNEY trials [3, 7]. This guideline’s aims were to: (i) provide guidance on use of SGLT-2 inhibitors in people with CKD, focusing on the potential to modify risk of kidney disease progression; and (ii) support safe implementation of SGLT-2 inhibitors into clinical practice in people with CKD.

Guideline structure

This manuscript provides an overview of the Recommendations made within the guideline with associated rationale. More information regarding the evidence for the efficacy and safety of SGLT-2 inhibition can be found in the full guideline document, together with licencing information, sick day guidance, and a full lay summary of the guideline. The full guideline document is provided as a Supplementary appendix. The guideline Working Group provided four types of Recommendations: (i) Use (who should be offered SGLT-2 inhibition); (ii) Implementation (how should SGLT-2 inhibition be used); (iii) Research (what are areas of ongoing clinical uncertainty); and (iv) Audit (how effective implementation can be demonstrated).

The Recommendations for Use and Recommendations for Implementation presented in this guideline are graded according to the two-tier grading system recommended by the UKKA (Table 1). Throughout the guideline, we use the term “recommend” where Recommendations are based on Grade 1 evidence, and “suggest” for those based on Grade 2 evidence. Recommendations for research are not graded, and we offer Recommendations for audit only for those Recommendations with Grade 1 evidence.

Table 1 UK Kidney Association’s grading system for Recommendations’ strength and evidence quality
Full size table

In this manuscript, we provide Recommendations for Use of SGLT-2 inhibition in people with and without diabetes separately, to acknowledge differences in the amount of available evidence (Table 2). We also provide Recommendations for implementation of SGLT-2 inhibition in practice, with a focus on safety considerations (Table 3). Finally, we discuss the use and implementation of SGLT-2 inhibition in populations of specific interest: people with type 1 diabetes, kidney transplant recipients, and people presenting with acute decompensated heart failure (Table 3). Research Recommendations are detailed in Table 4, and audit Recommendations listed in Table 5. Further information on the use of SGLT-2 inhibition, including a summary of UK licencing and a full lay summary of the guideline, can be found in the full document.

Table 2 Summary of Recommendations for Use
Full size table
Table 3 Summary of Recommendations for Implementation
Full size table
Table 4 Clinical research recommendations
Full size table
Table 5 Audit recommendations
Full size table

The Recommendations in this guideline were supported by a series of systematic literature searches for relevant SGLT-2 inhibitor randomised controlled trials, covering the period from database inception to 5th September 2022. Eligible studies were published parallel-group randomised controlled trials of SGLT-2 inhibitor versus placebo, active comparator or control, excluding phase 1 studies, studies in healthy volunteers, and non-English language reports. Trials were further subcategorised into large placebo-controlled trials and into subgroups of interest. Full details regarding search methodology can be found in the full guideline document (Supplementary appendix). The acknowledgements section and full guideline text provide more information on methods used to arrive at a Recommendation.

Recommendations for use of SGLT-2 inhibitors in people with type 2 diabetes

Due to the benefits of SGLT-2 inhibitors on kidney outcomes (CKD and acute kidney injury (AKI)) and cardiovascular risk:

  1. 1.

    We recommend initiating SGLT-2 inhibition in people with chronic kidney disease and type 2 diabetes, irrespective of primary kidney disease,* for any of the following 4 clinical scenarios (Grade 1A):

    1. (a)

      eGFR of 20–45 mL/min/1.73 m2

    2. (b)

      eGFR of > 45 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio (uACR) of ≥ 25 mg/mmol†

    3. (c)

      Symptomatic heart failure, irrespective of ejection fraction

    4. (d)

      Established coronary disease

* excludes people with polycystic kidney disease, type 1 diabetes, or a kidney transplant

† urinary protein-to-creatinine ratio of 35 mg/mmol can be considered equivalent

Rationale

CREDENCE, DAPA-CKD and EMPA-KIDNEY have consistently shown that SGLT-2 inhibition significantly and importantly reduces the risk of progression of CKD in broad ranges of people with CKD, including in people with diabetic kidney disease and kidney disease of non-diabetic aetiology [1,2,3,4]. SGLT-2 inhibitors also reduce risk of acute kidney injury and cardiovascular disease [4, 5]. Participants were enrolled down to an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73m2, and there is no evidence that the beneficial effects of SGLT-2 inhibition on kidney disease progression or cardiovascular risk are attenuated across the spectrum of eGFR studied [4]. In EMPA-KIDNEY, participants were enrolled with eGFR 20-45 mL/min/1.73m2 irrespective of uACR, or eGFR >45 mL/min/1.73m2 with uACR ≥23 mg/mmol [3]. EMPA-KIDNEY and DAPA-CKD both demonstrated consistent benefits irrespective of primary kidney diagnosis subdivided by diabetic kidney disease, ischaemic and hypertensive nephropathy, and glomerular disease (Fig. 2) [1, 3, 4]. Among non-albuminuric kidney disease, data from eGFR slope analyses in EMPA-KIDNEY demonstrates reductions in rate of eGFR decline of a magnitude that would be expected to translate into meaningful reductions in progression of CKD (Fig. 3), which is supported by similar findings in eGFR slope analyses from EMPEROR-REDUCED, EMPEROR-PRESERVED, DAPA-HF and DELIVER [3, 8,9,10,11,12]. We therefore provide grade 1A Recommendation for use in people with eGFR 20-45 mL/min/1.73m2 or with eGFR ≥45 mL/min/1.73m2 and uACR ≥25 mg/mmol. Note that the 25 mg/mmol threshold for uACR was chosen pragmatically, given that this value is expected to be easier to recall for practicing clinicians than a cut-off of 23 mg/mmol, as is commonly used in the CKD trials.

Fig. 2
figure 2

Effects of SGLT-2 inhibition on kidney disease progression by primary kidney diagnosis (adapted from [4]). *RR in the diabetic kidney disease or nephropathy subgroup excluding SCORED (which did not formally assess primary kidney disease) is 0.59 (95% CI 0.52–0.68). Figure licensed under Creative Commons CC-BY license

Full size image
Fig. 3
figure 3

Effects of empagliflozin versus placebo on the rate of eGFR decline in EMPA-KIDNEY, by key subgroups (adapted from [3]). Mean annual rate of change in eGFR (mL/min/1.73m2/year) from baseline to final follow-up visit (total slope) and from two months to final follow-up visit (chronic slope). The long-term (i.e. chronic slope) is emphasised as other data has demonstrated that the acute negative eGFR dip on initiation of SGLT2 inhibitors reverses on cessation, which is not accounted for in total slope analyses. This is particularly relevant when studying people whose kidney disease progresses slowly over short periods of time (e.g. 2 years), during which time progression is likely to be less than the acute negative eGFR dip (as was the case in the uACR < 30 mg/g group). Figure licensed under CC BY-ND 4.0 International license

Full size image

Consistent findings from five SGLT-2 inhibitor trials in people with symptomatic heart failure have demonstrated that SGLT-2 inhibition reduces the risk of cardiovascular death or hospitalisation for heart failure among this population [4, 6, 7, 11,12,13,14]. These findings have been demonstrated in people with reduced and preserved ejection fraction, and in people with recent hospitalisation for worsening heart failure [7, 12, 14]. There has been no evidence that the cardiac benefits of SGLT-2 inhibition are modified by diabetes status or by eGFR [4]. Among CKD populations, cardiovascular death or hospitalisation for heart failure has been shown to be reduced by SGLT-2 inhibition in CREDENCE, SCORED and DAPA-CKD [1, 2, 15]. The totality of evidence indicates a reduction of these outcomes of approximately one quarter in people treated with SGLT-2 inhibition compared to placebo [4]. We therefore provide grade 1A Recommendation for use in people with CKD for this indication. Those with prior coronary disease are at high risk of major adverse cardiovascular events (MACE) and heart failure and are included in this Recommendation based on the totality of the evidence [5].

  1. 2.

    We suggest initiating SGLT-2 inhibition to modify cardiovascular risk and slow rate of kidney function decline in people with an eGFR > 45–60 mL/min/1.73m2 and a uACR of < 25 mg/mmol, recognising effects on glycaemic control will be limited (Grade 2B).

Rationale

Meta-analysis of large randomised clinical trials of SGLT-2 inhibition indicates that cardiovascular benefits of SGLT-2 inhibition, particularly reducing the risk of cardiovascular death or hospitalisation for heart failure, are present irrespective of trial-level average eGFR [4]. The benefits of SGLT-2 inhibition in terms of reducing progression of kidney disease are also not modified by eGFR in individual trials [1,2,3]. eGFR slope analyses from heart failure and CKD trials consistently demonstrate reduced rates of kidney function decline among people treated with SGLT-2 inhibition, including those without significant albuminuria, as demonstrated in EMPA-KIDNEY (Fig. 3) [3, 8,9,10,11,12]. EMPEROR-REDUCED, EMPEROR-PRESERVED, DAPA-HF and DELIVER all show reductions in the rate of kidney function decline with SGLT-2 inhibition compared to placebo, while in EMPEROR-REDUCED this reduction in rate of eGFR decline is present in the presence and absence of CKD and across the spectrum of albuminuria [8,9,10,11,12]. Therefore, while this population has not been directly studied in randomised trials, there is indirect evidence to support reduction in cardiovascular risk and reduced rate of kidney function decline in this group, for which we provide a grade 2B Recommendation.

  1. 3.

    We suggest clinicians consider initiating SGLT-2 inhibition in people with an eGFR below 20 mL/min/1.73m2 to slow progression of kidney disease (Grade 2B)

Rationale

Clinical trials of SGLT-2 inhibition conducted in populations with CKD have continued SGLT-2 inhibition until the initiation of kidney replacement therapy, providing indirect evidence to support the use of this SGLT-2 inhibition in this population [1,2,3]. Furthermore, data from EMPA-KIDNEY indicates that the benefit of SGLT-2 inhibition in terms of progression of kidney disease is not attenuated in people with an eGFR < 20 mL/min/1.73m2 (Fig. 4). There is no suggestion from the data that kidney benefits of SGLT-2 inhibition begin to attenuate down to an eGFR of 15 mL/min/1.73m2, and those with very low eGFR are at particularly high risk (Fig. 4). We therefore provide a 2B Recommendation for use in people with eGFR < 20 mL/min/1.73m2.

Fig. 4
figure 4

Effects of empagliflozin versus placebo on the primary outcome of EMPA-KIDNEY, by baseline eGFR (post-hoc analysis). Post-hoc analysis of unpublished data from EMPA-KIDNEY

Full size image

Recommendations for use of SGLT-2 inhibitors in people without diabetes

  1. 1.

    We recommend initiating SGLT-2 inhibition in people with chronic kidney disease, irrespective of primary kidney disease,* for any of the following clinical scenarios (Grade 1A):

    1. a.

      eGFR of ≥ 20 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio (uACR) of ≥ 25 mg/mmol†

    2. b.

      Symptomatic heart failure, irrespective of ejection fraction

* excludes people with polycystic kidney disease, type 1 diabetes, or a kidney transplant

† urinary protein-to-creatinine ratio of 35 mg/mmol can be considered equivalent

Rationale

SGLT-2 inhibition has been shown to be effective in people with albuminuric chronic kidney disease across broad population, including people with and without type 2 diabetes, and down to an eGFR of 20 mL/min/1.73m2 [1,2,3,4]. Meta-analysis of CKD trials and all SGLT-2 inhibitor trials demonstrates that the kidney benefits of SGLT-2 inhibition are not modified by the presence or absence of diabetes [4]. Furthermore, DAPA-CKD and EMPA-KIDNEY both indicate consistent benefits irrespective of primary kidney disease, with benefits observed in glomerular disease of a similar magnitude to those seen in diabetic kidney disease [1, 3, 4].

SGLT-2 inhibition has been demonstrated to reduce the risk of heart failure hospitalisation in people with stable established symptomatic heart failure with reduced ejection fraction (HFrEF) by the DAPA-HF and EMPEROR-REDUCED trials, with relative effects similar in people with and without DM [11, 13]. Data from EMPEROR-PRESERVED and DELIVER confirm benefits on heart failure complications in people with heart failure with preserved ejection fraction (HFpEF), including people without DM [7, 12]. The four large trials recruited a substantial proportion of people with CKD, with cardiac benefits appearing to be unmodified by moderately reduced levels of eGFR [4, 6]. We therefore provide a grade 1A Recommendation for use of SGLT-2 inhibition in people without DM with an eGFR ≥20 mL/min/1.73m2 and uACR ≥25 mg/mmol, or those with symptomatic heart failure. Note that the 25 mg/mmol threshold for uACR was chosen pragmatically, given that this value is expected to be easier to recall for practicing clinicians than a cut-off of 23 mg/mmol, as is commonly used in the CKD trials.

  1. 2.

    We recommend initiating SGLT-2 inhibition to slow rate of kidney function decline in people with an eGFR of 20–45 mL/min/1.73 m2 and a uACR of < 25 mg/mmol* (Grade 1B)

* urinary protein-to-creatinine ratio of 35 mg/mmol can be considered equivalent.

Rationale

The excellent safety profile of SGLT-2 inhibition in people with CKD without DM has been established in nearly 5000 such people from DAPA-CKD and EMPA-KIDNEY [1, 3]. DAPA-CKD and EMPA-KIDNEY demonstrated beneficial effects across the spectrum of eGFR in terms of progression of kidney disease in people with and without diabetes [4] (Fig. 5). Furthermore, EMPA-KIDNEY also showed that among people without albuminuria rate of kidney function decline (chronic eGFR slope) was reduced by 0.78 mL/min/1.73m2 per year in participants with A1 levels of albuminuria (<30 mg/g) to a rate of -0.11 mL/min/1.73m2 per year, and by 1.20 mL/min/1.73m2 per year in participants with A2 levels (30-299 mg/g; Fig. 3) [3]. Such absolute benefits would be predicted to translate into clinically meaningful reductions in progression of kidney disease, even among people with low albuminuria at baseline. Among those with low levels of albuminuria and low eGFR at initiation, such effects on eGFR decline could translate into delay in the onset of kidney failure if used over a period of years. Furthermore, SGLT-2 inhibition has been shown to reduce the risk of AKI and cardiovascular risk [4], as well as hospitalisations from any cause [3] . Given the clear magnitude of benefit of SGLT-2 inhibition in this population and the reassuring safety profile, we provide a grade 1 Recommendation for this statement. However, at present only EMPA-KIDNEY provides direct evidence in this population, with further supporting evidence obtained from eGFR slopes of the trials in heart failure (i.e. grade B level of evidence). Cost-effective analyses in this group would provide valuable additional information.

  1. 3.

    We suggest clinicians consider initiating SGLT-2 inhibition in people with an eGFR below 20 mL/min/1.73m2 to slow progression of kidney disease (Grade 2B)

Fig. 5
figure 5

Effects of SGLT-2 inhibitors on kidney disease progression by population (adapted from [4]). Kidney disease progression was defined as a sustained ≥ 50% decline in eGFR from randomisation, kidney failure, or death from kidney failure. Data not available for SOLOIST-WHF. Figure licensed under Creative Commons CC-BY license

Full size image

Rationale

Two of the four clinical trials of SGLT-2 inhibition conducted in people with CKD have enrolled people without diabetes (DAPA-CKD and EMPA-KIDNEY), and in both trials SGLT-2 inhibition has been continued below an eGFR of 20 mL/min/1.73m2 without evidence of increased adverse events [1, 3]. In EMPA-KIDNEY, in which over half of the participants did not have diabetes, SGLT-2 inhibition was shown to have consistent relative benefits across the spectrum of eGFR, including among people with eGFR < 20 mL/min/1.73m2 (Fig. 4) [3]. Given that people with low eGFR are at high risk of progression to kidney failure, the absolute benefit is likely to be considerable for this population, irrespective of diabetes status. We therefore provide a grade 2B Recommendation for initiation of use of SGLT-2 inhibition for people without type 2 DM with eGFR < 20 mL/min/1.73m2.

Recommendations for implementation in people with or without type 2 diabetes

  1. 1.

    We recommend using SGLT-2 inhibitors with demonstrated efficacy for their given indications (Grade 1A).

Rationale

Government regulators review data from randomised trials and assess their reliability through regulatory inspections. Regulatory licences/indications therefore provide a key guide to which SGLT-2 inhibitors have generated definitive evidence of efficacy and safety for a given use. We therefore recommend selecting SGLT-2 inhibitors according to these licensed indications, wherever possible (summaries of which are provided in section 4 of the Supplementary appendix).

  1. 2.

    We recommend using clinically appropriate single agent renin-angiotensin system (RAS) blockade in combination with SGLT-2 inhibition, wherever RAS blockade is indicated and tolerated (Grade 1A)

Rationale

These clinical practice guidelines pertain to use of SGLT-2 inhibition in people with CKD. The standard of care in many forms of CKD is the use of RAS blockers [16, 17], with clear evidence of benefit in diabetic nephropathy [18, 19]. All CREDENCE participants were on stable maximally tolerated RAS blockade [2], as were 97% of DAPA-CKD participants [1] and 85% of participants in EMPA-KIDNEY [3]. We therefore provide a grade 1A Recommendation to prescribe RAS blockade and ensure clinically appropriate dosing alongside any SGLT-2 inhibitor use. Note that it has been suggested that, mechanistically, SGLT-2 inhibition may have the potential to activate RAS [20]. However the large trials in people with type 2 DM at high atherosclerotic cardiovascular risk have been combined in meta- analysis and have raised a hypothesis that the benefits of SGLT-2 inhibitors on kidney disease progression could extend to people with type 2 DM not on RAS blockade [21]. The lack of heterogeneity of effect of empagliflozin on the primary composite outcome stratified by use of RAS inhibition in EMPA-KIDNEY lends further support to this hypothesis [3].

Note that we recommend single agent RAS blockade, as combination therapy (i.e. dual blockade with angiotensin-converting enzyme inhibitor [ACEi] plus angiotensin receptor blocker [ARB]) has been found to increase the risk of serious hyperkalaemia or acute kidney injury, and has not been shown to importantly slow CKD progression [22].

  1. 3.

    We suggest following NICE guidelines on use of uACR for screening of albuminuria (NICE NG203). We recognise that more pragmatic approaches to identifying risk of kidney disease progression may be necessary whilst local access to uACR measurement is improved (Grade 2C).

Rationale

Many factors can cause transient increases in albuminuria (including urinary tract infection, exercise, and menstruation) and as such, the National Institute for Health and Care Excellence (NICE) [23] and other international guideline groups [24] recommend that repeat testing should take place within 3 months if a single uACR result is between 3-69 mg/mmol. An early morning sample offers some advantages due to reduced impact of hydration status and exercise [25], but if unavailable, random sampling may still offer a reliable indication of total daily albuminuria [26]. A uACR value ≥70 mg/mmol generally does not require further confirmation, as this is consistent with clinically significant proteinuria [27].

We agree with the statement within the NICE CKD guidelines that reagent strips and protein-to-creatinine ratio measurements should not be used to quantify albuminuria [23]. Large-scale meta-analysis and other observational data have shown that dipstick values using reagent strips are neither sensitive, nor specific enough to predict uACR accurately [28]. However, we recognise that uACR testing may not be regularly undertaken in some areas of the UK, and local methods of assessing risk may need to be used to ensure those at risk are offered SGLT-2 inhibition.

  1. 4.

    We recommend that SGLT-2 inhibition can be continued until the need for dialysis or kidney transplantation arises (Grade 1A).

Rationale

Data from CKD trials include many hundreds of participants with an eGFR below 20 mL/min/1.73m2 [1,2,3]. Continued use of SGLT-2 inhibitors until the need for dialysis or kidney transplantation was the practice in these trials, which have confirmed benefits exceed any harms. In subgroup analyses, kidney benefits are unmodified by baseline eGFR. At a population level, people with a low eGFR are at highest absolute risk of kidney failure, and are therefore most likely to benefit (in absolute terms).

  1. 5.

    We suggest that co-prescription of SGLT-2 inhibition with MRA can be considered, where each are individually indicated (Grade 2B).

Rationale

Subgroup analyses from the SGLT-2 inhibitor trials in non-CKD populations suggest cardiac and kidney benefits are likely to be maintained in people co-prescribed an MRA with an SGLT-2 inhibitor, with no increased risk of hyperkalaemia caused by SGLT-2 inhibitor use [6, 14, 29,30,31,32,33,34]. CREDENCE, DAPA-CKD and EMPA-KIDNEY provide reassuring evidence that SGLT-2 inhibition does not usually cause hyperkalaemia in CKD populations [1,2,3]. We therefore provide a grade 2B suggestion that MRA can be used with SGLT-2 inhibitors. Note that guidance on how to monitor for changes in eGFR and potassium in those on MRA are outside of the scope of this guideline.

  1. 6.

    We suggest the beneficial effects of SGLT-2 inhibition on kidney disease progression or risk of heart failure hospitalisation are likely to be a class effect (Grade 2B)

Rationale

We have recommended using SGLT-2 inhibitors with demonstrated efficacy for their given indications, but as more large trials report results testing the available SGLT-2 inhibitors in overlapping populations, it is increasingly apparent that any differences between the individual molecules do not appear to create large differences in clinical efficacy. For example, CREDENCE (canagliflozin), DAPA-CKD (dapagliflozin) and EMPA-KIDNEY (empagliflozin) reported relative risk reductions on their respective kidney disease progression outcomes which were comparable in their respective (sub)populations with type 2 DM [1,2,3,4, 35]. Beneficial effects on cardiovascular death or hospitalisation for heart failure were consistent in the CKD trials with the totality of evidence across all SGLT-2 inhibitor trials, including those in heart failure-specific populations [4]. Likewise, the HFrEF trials DAPA-HF (dapagliflozin) and EMPEROR-REDUCED (empagliflozin) [11, 13], and the HFpEF trials DELIVER (dapagliflozin) and EMPEROR-PRESERVED (empagliflozin) [7, 12], share similar designs and results of primary and secondary assessments overall and across subgroups are remarkably consistent [6].

Relative risk reductions on major adverse cardiovascular events (MACE) across key cardiovascular safety trials [36] and trials in dedicated CKD populations are also not statistically different from each other [1, 15]. Meta-analyses demonstrate consistent benefits of SGLT-2 inhibition in terms of cardiovascular and kidney benefits without apparent heterogeneity by class overall and stratified by diabetes status [4, 5]. We are of the opinion that the larger effects of empagliflozin on cardiovascular death in EMPA-REG OUTCOME [37], and the larger effects on non-cardiovascular death in DAPA-CKD compared to other SGLT-2 inhibitor trials [5, 38] are more likely represent the play of chance or be caused by factors other than minor differences in the biological action of different SGLT-2 inhibitors. We therefore suggest there is increasing evidence that the cardiac and kidney benefits of SGLT-2 inhibition represent a class effect.

It should be noted, however, that SGLT-2 inhibitors differ in their respective receptor selectivity and there may be an increased propensity to cause diarrhoea and volume depletion when using SGLT-2 inhibitors that also meaningfully inhibit gut SGLT-1 (e.g. sotagliflozin [14]). Selectivity for SGLT-2 over SGLT-1 ranges from: ~20:1 for the dual SGLT-1/2 inhibitor sotagliflozin [39], and from ~250:1 for canagliflozin to ~2500:1 for empagliflozin [40] for the more selective SGLT-2 inhibitors.

Recommendations for implementation: Diabetic Ketoacidosis (DKA)

  1. 1.

    We recommend that people with type 1 DM should only have SGLT-2 inhibitors initiated under the strict direction of the diabetes team (see section 7a of the supplementary appendix) (Grade 1C).

  2. 2.

    We recommend that people with type 2 DM at greater risk of DKA (defined in Table 5a.1 of the supplementary appendix) should have SGLT-2 inhibitors initiated with caution after discussion with the diabetes team (Grade 1C).

  3. 3.

    We recommend SGLT-2 inhibitors are discontinued when an individual develops DKA (Grade 1A).

  4. 4.

    We suggest that after an episode of DKA and where a clear contributing factor has been identified, there should be discussion with the person and clinical team to establish whether the benefits of re- introducing an SGLT-2 inhibitor outweigh the risks (Grade 2D).

  5. 5.

    When initiating SGLT-2 inhibitors, we suggest that individuals should be advised on the signs and symptoms of DKA and be instructed to temporarily withhold SGLT-2 inhibitors and to seek immediate medical advice if symptoms develop (Grade 1C).

  6. 6.

    We recommend always offering advice on sick day guidance when initiating SGLT-2 inhibitors and reminding them of this at every medication review (Grade 1C).

  7. 7.

    We suggest that individuals taking SGLT-2 inhibitors should be advised against following a ketogenic diet (Grade 2C).

  8. 8.

    We suggest that for people who choose to intermittently fast (e.g. for Ramadan), and particularly for those who are elderly, on diuretics or have CKD, consider withholding SGLT-2 inhibitors for the duration of the fasting period and for those people with diabetes ketone testing should be undertaken if unwell (Grade 2D).

Rationale

The evidence from the studies reviewed indicates that diabetic ketoacidosis (DKA) is a recognised complication in people treated with SGLT-2 inhibitors and that it is more commonly found in conjunction with dehydration or infection [1,2,3,4]. DKA is also likely to occur more frequently in people who are insulin deficient which would include people with type 1 DM, people with type 2 DM with a relative insulin deficient phenotype, and situations where people on insulin have their insulin dose reduced substantially [41]. These Recommendations will allow clinicians to use SGLT-2 inhibitors in those who are likely to benefit from this treatment and yet also minimise the risk of the complication of DKA.

Recommendations for implementation: hypoglycaemia

  1. 1.

    We recommend considering reducing the dose of insulin/SUs/meglitinides when initiating SGLT-2 inhibitors to reduce the risk of hypoglycaemia (Grade 1C).

  2. 2.

    We recommend that when initiating SGLT-2 inhibitors in people taking SUs (e.g. gliclazide) or meglitinides (e.g. repaglinide) when the HbA1c < 58 mmol/mol AND eGFR > 45 mL/min/1.73m2, consider reducing dose of SU or meglitinide by 50% to reduce risk of hypoglycaemia (Grade 1C).

  3. 3.

    We recommend that when starting SGLT-2 inhibitors in people taking insulin when the HbA1c < 58 mmol/mol AND eGFR > 45 mL/min/1.73m2, consider reducing the insulin dose by 20% to avoid hypoglycaemia (Grade 1C).

  4. 4.

    We recommend that when starting SGLT-2 inhibitors in people taking only metformin ± pioglitazone ± DPP-4i/gliptins or GLP-1RA therapy, no dosage adjustment is necessary (Grade 1C).

Rationale

SGLT-2 inhibitors are effective drugs at reducing hyperglycaemia when they are used in people with preserved kidney function (e.g. eGFR >60 mL/min/1.73m2), however, their glycaemic effectiveness reduces as the eGFR declines [42, 43]. Where a treatment for DM carries a risk of hypoglycaemia (such as SUs and insulin use), the addition of an SGLT-2 inhibitor may potentiate that risk, particularly if baseline glycaemic control is reasonable at the time of initiation of treatment. There is no evidence that SGLT-2 inhibitors cause significant hypoglycaemia on their own or in addition with DM medicines that are not associated with hypoglycaemia [4, 44, 45].

Recommendations for implementation: acute kidney injury (AKI), hypovolaemia and potassium

  1. 1.

    We recommend that individuals initiated on an SGLT-2 inhibitor do not routinely require an early assessment of kidney function or potassium following initiation of treatment (Grade 1C).

  2. 2.

    We suggest that if an individual has a kidney function assessment within the first few weeks post initiation of an SGLT-2 inhibitor, a decline in eGFR needs to be interpreted with caution and in the context of an expected drug effect to avoid unwarranted discontinuation of treatment (Grade 2B).

  3. 3.

    We suggest that individuals on diuretics are counselled on the symptoms of hypovolaemia and advised to seek medical attention if they develop any such symptoms after starting SGLT-2 inhibition (Grade 2B).

  4. 4.

    We suggest that clinicians consider an early clinical review and if appropriate a diuretic or antihypertensive dose reduction in individuals they consider at high risk of hypovolaemia (Grade 2C).

  5. 5.

    We recommend that SGLT-2 inhibitors are temporarily withheld during acute illness (Grade 1C).

Rationale

SGLT-2 inhibitors have proven benefit in relation to reducing the rate of long-term decline in kidney function in certain groups of people with CKD. The means by which they provide this benefit may involve changes to intraglomerular pressure and reduction in hyperfiltration at an individual glomerulus level. This can result in a reduction in eGFR over the initial few weeks following initiation of SGLT-2 inhibitors, which is relatively small, largely reversible and should not usually be seen as an adverse effect of the drug [46].

None of the major studies have demonstrated an increased risk of acute kidney injury (AKI) in people treated with SGLT-2 inhibitors, and it seems likely they have renal tubular protective effects that reduce risk of AKI [4]. It is therefore important that early changes in eGFR that occur following initiation of SGLT-2 inhibitors do not routinely result in withdrawal of SGLT-2 inhibition when people are likely to gain significant benefit from them.

In addition, SGLT-2 inhibitors have a combined osmotic diuretic and natriuretic effect, so clinicians and the people treated with SGLT-2 inhibitors need to be aware of this effect in order to ensure that any risk of hypovolaemia is minimised.

Recommendations for implementation: peripheral vascular disease (PVD) and amputation risk

  1. 1.

    We suggest avoiding initiation of SGLT-2 inhibitors in the presence of active foot disease (infection, ulceration and ischaemia) and withholding treatment in those who develop foot complications whilst taking an SGLT-2 inhibitor (Grade 2B).

  2. 2.

    We suggest a shared decision-making approach, with appropriate counselling on risks and benefits of treatment and the importance of routine preventative foot care measures for:

    • Individuals at high risk of amputation (previous amputations, existing PVD, peripheral neuropathy)

    • Re-initiation of SGLT-2 inhibitors after treatment and satisfactory resolution of a foot complication that occurred whist taking SGLT-2 inhibitors (Grade 2B).

Rationale

A significant finding from a single large trial using the SGLT-2 inhibitor canagliflozin alerted clinicians to the possibility that SGLT-2 inhibitors could increase the risk of lower limb amputations [47]. This finding has not been confirmed in other large trials [4] and furthermore it is important to appreciate that people with peripheral vascular disease (PVD) are a group of individuals who have more to gain from the initiation of SGLT-2 inhibitors in relation to protection against risk of cardiovascular death, myocardial infarction, heart failure complications and progression of CKD. It is therefore important not to exclude these individuals from the potential benefits of SGLT-2 inhibitors, but to ensure that these medicines are used appropriately and safely in people at risk, or with evidence of PVD.

Recommendations for implementation: fracture risk

  1. 1.

    In people with CKD treated with SGLT-2 inhibitors, we suggest monitoring of bone parameters including calcium, phosphate and parathyroid hormone should be performed as appropriate for CKD stage (NICE NG203) (Grade 2D).

Rationale

Whilst there has been report of an increased risk of fractures in one trial where participants were treated with canagliflozin, this has not been confirmed in any other study and may represent the play of chance [4, 47]. People with CKD are at increased risk of bone disease and their clinician should be monitoring them to ensure that interventions are utilised to maintain good bone health irrespective of the prescription of SGLT-2 inhibitors. NICE NG203 CKD guidance is available at https://www.nice.org.uk/guidance/ng203.

Recommendations for implementation: multimorbidity and frailty

  1. 1.

    We suggest an approach to care that takes account of frailty and multimorbidity where these apply. This can include:

    • Establishing the person’s goals, values and priorities

    • Consideration of the balance of disease and treatment burden (for example, prognostic benefits in people with limited life expectancy or frailty)

    • Agreeing an individualised management plan (Grade 2D).

Rationale

When making decisions on which individuals would benefit from SGLT-2 inhibition one has to consider the participants included in the relevant trials that provided the evidence for their use. These trials generally excluded people with greater degrees of frailty and certain comorbidities. Therefore, caution must be exercised when extending evidence of safety (and perhaps also benefit) of SGLT-2 inhibitors to such individuals, although one needs to also consider at the same time that many of these individuals, and particularly those with heart failure, are likely to achieve significant benefit from the use of SGLT-2 inhibitors.

Recommendations for implementation: mycotic genital infections and fournier’s gangrene

  1. 1.

    We recommend that all people are counselled on the risks of mycotic genital infections prior to initiation of SGLT-2 inhibitors (Grade 1D).

  2. 2.

    We recommend that all people are counselled on self-care to maintain good genital hygiene (Grade 1C).

  3. 3.

    We recommend that all people are counselled on the symptoms of mycotic genital infections and how to seek help including self-management (Grade 1D).

  4. 4.

    We suggest that for those individuals with a history of recurrent mycotic genital infections on SGLT-2 inhibition, consideration is given to offering prophylactic anti-fungal treatment, which should be reviewed after 6 months of therapy or earlier if clinically indicated (Grade 2D).

  5. 5.

    We suggest that SGLT-2 inhibitor therapy can be continued during the treatment of mycotic genital infections (Grade 2D).

  6. 6.

    We highlight the specific MHRA warning and suggest that all people are counselled on the symptoms of Fournier’s gangrene and advised to stop SGLT-2 inhibitors and to seek urgent help if they develop such symptoms (Grade 2D).

Rationale

Mycotic genital infections are recognised to occur more frequently in people treated with SGLT-2 inhibitors (on average risk is about 3-4-fold higher) and particularly in those individuals with DM [4, 48]. These infections are usually mild and easily treated. Good clinical care should include ensuring that individuals prescribed SGLT-2 inhibitors are aware of this complication, how to reduce the risk of it occurring and appropriate actions should they develop symptoms consistent with mycotic genital infections.

In contrast to mycotic genital infections, Fournier’s gangrene is a rare condition that results from bacterial infection and it requires prompt and intensive medical and surgical management. This disorder is identified in people with DM and whilst the evidence to suggest that it may be increased in people treated with SGLT-2 inhibitors is limited to post-marketing surveillance [49], all people starting SGLT-2 inhibitors should be advised on the symptoms of Fournier’s gangrene and what to do if they develop such symptoms.

Recommendations for implementation: urinary tract infection

  1. 1.

    We recommend temporary discontinuation of SGLT-2 inhibitors when treating acute pyelonephritis or urosepsis (Grade 1C).

Rationale

Randomised data from major trials show the increased risk of urinary tract infections (UTIs) with SGLT-2 inhibitors is small [4]. However, these drugs are being prescribed in people who have a high risk of UTIs and effective prompt management of these infections should be undertaken.

Recommendations for implementation: children, pregnancy and breastfeeding

  1. 1.

    We suggest that all women of child-bearing potential are counselled, prior to conception, on the risks of SGLT-2 inhibitors during pregnancy (Grade 2D).

  2. 2.

    We suggest SGLT-2 inhibitor therapy is discontinued upon planning, suspicion or confirmation of pregnancy (Grade 2D).

  3. 3.

    We suggest SGLT-2 inhibitors are not used in women who are breastfeeding (Grade 2D).

Rationale

There is theoretical evidence to advise against using these drugs in people either planning pregnancy, who become pregnant or who are breastfeeding [50,51,52,53]. Clinical trials in the paediatric setting are suggested.

Recommendations for implementation in specific populations: people with type 1 diabetes

  1. 1.

    We recommend that SGLT-2 inhibitors be initiated in people with type 1 DM, only under the strict direction of the diabetes team (Grade 1C).

  2. 2.

    We suggest considering referring people with type 1 DM to the specialist diabetes team, for consideration of an SGLT-2 inhibitor, if they have an eGFR ≥ 20 mL/min/1.73m2, and a uACR ≥ 25 mg/mmol despite being on maximum tolerated ACEi/ARB (Grade 2C).

  3. 3.

    We recommend all people with type 1 DM started on SGLT-2 inhibitors be provided with ketone monitoring, be advised on the signs and symptoms of DKA and to seek immediate medical advice if any of these symptoms develop or ketone levels are > 0.6 mmol/L (Grade 1B).

Rationale

There is currently insufficient evidence to recommend the use of SGLT-2 inhibitors as an adjunct to existing therapies in the management of diabetic nephropathy in people with type 1 DM. Evidence of kidney benefits in people with type 2 DM makes this plausible but such results cannot be readily extrapolated to people with type 1 DM. Clinicians may wish to discuss treatment options with their patients and other specialists in cases where proteinuria persists despite current standard treatment. Thresholds for referral to the specialist diabetes team have been updated in the current version of this guideline in line with evidence available from trials of SGLT-2 inhibition irrespective of the presence or absence of diabetes. Furthermore, the grading for Recommendation number 2 has been increased from 2D to 2C, given evidence available from the InTandem3 trial [54].

Recommendations for implementation in specific populations: kidney transplant recipients

  1. 1.

    There is currently insufficient evidence on safety and efficacy to provide Recommendations for use of SGLT-2 inhibition in people with a functioning kidney transplant.

  2. 2.

    Any use of SGLT-2 inhibition to treat diabetes mellitus in a kidney transplant recipient should be evaluated by multi-disciplinary discussion (Grade 2D)

Note: effects on glycaemic control at an eGFR < 60 mL/min/1.73m2 in people with a kidney transplant appear small and potential risk of complications from urinary tract infection should be considered.

Recommendations for implementation in specific populations: acute decompensated heart failure

We suggest initiating SGLT-2 inhibition in people with CKD (eGFR ≥ 20 mL/min/1.73m2) with acute decompensated heart failure. (2B).

Rationale

Multiple small-scale randomised controlled trials provide evidence that SGLT-2 inhibition is safe in a population presenting to hospital with acute decompensated heart failure (ADHF) [55,56,57,58,59]. Furthermore, the moderate-sized EMPULSE trial demonstrates that individuals treated with SGLT-2 inhibition for ADHF are more likely to yield clinical benefit than those treated with placebo [60]. Trials in ADHF enrolled people with eGFR > 15 mL/min/1.73m2, with the largest trial (EMPULSE) enrolling those with eGFR ≥ 20 mL/min/1.73m2. More evidence from large, well-conducted randomised controlled trials (such as the DAPA ACT HF-TIMI 68 trial [61]) will provide more comprehensive evidence to support this Recommendation.

See Section 2 & 3 for Recommendations for use in other forms of heart failure or to modify cardiovascular risk.

Clinical research and audit recommendations in people with or without type 2 diabetes

A summary of clinical research Recommendations can be found in Table 4, and a summary of audit Recommendations can be found in Table 5.

Availability of data and materials

Not applicable.

References

  1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

    Article  CAS  PubMed  Google Scholar 

  2. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

    Article  CAS  PubMed  Google Scholar 

  3. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022;388(2):117–27.

    Article  Google Scholar 

  4. Nuffield Department of Population Health Renal Studies Group and the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–801.

    Article  Google Scholar 

  5. Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine. 2021;41:101163.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–67.

    Article  CAS  PubMed  Google Scholar 

  7. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.

    Article  PubMed  Google Scholar 

  8. McCausland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, et al. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023;8(1):56–65.

  9. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and kidney benefits of Empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143(4):310–21.

    Article  CAS  PubMed  Google Scholar 

  10. Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, et al. Efficacy of Dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction. Circulation. 2021;143(4):298–309.

    Article  CAS  PubMed  Google Scholar 

  11. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.

    Article  CAS  PubMed  Google Scholar 

  12. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–61.

    Article  CAS  PubMed  Google Scholar 

  13. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008.

    Article  CAS  PubMed  Google Scholar 

  14. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117–28.

    Article  CAS  PubMed  Google Scholar 

  15. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2020;384(2):129–39.

    Article  PubMed  Google Scholar 

  16. Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) https://kdigo.org/guidelines/ckd-evaluation-and-management/ (Accessed 28th Dec 2020).

  17. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73–87.

    Article  CAS  PubMed  Google Scholar 

  18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329(20):1456–62.

    Article  CAS  PubMed  Google Scholar 

  19. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.

    Article  CAS  PubMed  Google Scholar 

  20. Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int. 2014;86(5):1057–8.

    Article  CAS  PubMed  Google Scholar 

  21. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–54.

    Article  CAS  PubMed  Google Scholar 

  22. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–903.

    Article  CAS  PubMed  Google Scholar 

  23. National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. London: NICE; 2014. p. CG182. https://www.nice.org.uk/guidance/cg182 (Accessed 02 June 2021).

  24. KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150 (2013. p. 1-150).

    Google Scholar 

  25. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol. 2009;20(2):436–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309(25):1543–6.

    Article  CAS  PubMed  Google Scholar 

  27. UK Kidney Association. The UK eCKD Guide. https://renal.org/health-professionals/information-resources/uk-eckd-guide/proteinuria (Accessed 02 June 2021).

  28. Park JI, Baek H, Kim BR, Jung HH. Comparison of urine dipstick and albumin:creatinine ratio for chronic kidney disease screening: A population-based study. PLoS One. 2017;12(2):e0171106.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Provenzano M, Jongs N, Vart P, Stefánsson BV, Chertow GM, Langkilde AM, et al. The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, Dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep. 2022;7(3):436–43.

    Article  PubMed  Google Scholar 

  30. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with Ertugliflozin in Type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.

    Article  CAS  PubMed  Google Scholar 

  31. Docherty KF, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020;41(25):2379–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ferreira JP, Butler J, Zannad F, Filippatos G, Schueler E, Steubl D, et al. Mineralocorticoid receptor antagonists and Empagliflozin in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2022;79(12):1129–37.

    Article  CAS  PubMed  Google Scholar 

  33. Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and Empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397–407.

    Article  CAS  PubMed  Google Scholar 

  34. Shen L, Kristensen SL, Bengtsson O, Bohm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 2021;9(4):254–64.

    Article  PubMed  Google Scholar 

  35. Wheeler DC, Stefansson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31.

    Article  CAS  PubMed  Google Scholar 

  36. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148–58.

    Article  PubMed  Google Scholar 

  37. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  PubMed  Google Scholar 

  38. Heerspink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021;42(13):1216–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019;18(1):20.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90.

    Article  CAS  PubMed  Google Scholar 

  41. Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors, 2016. http://www.diabetologists-abcd.org.uk/Position_Papers/ABCD_DKA_SGLT2.pdf (Accessed 15th December 2022)

  42. Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231–44.

    Article  CAS  PubMed  Google Scholar 

  43. Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson F, Heerspink HJL. Differential effects of Dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017;12(5):751–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S, et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(1):142–7.

    Article  CAS  PubMed  Google Scholar 

  45. Harris SB, Mequanint S, Miller K, Reichert SM, Spaic T. When insulin therapy fails: the impact of SGLT2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2017;40(10):e141–2.

    Article  PubMed  Google Scholar 

  46. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323–34.

    Article  CAS  PubMed  Google Scholar 

  47. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

    Article  CAS  PubMed  Google Scholar 

  48. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23(1):3–13.

    Article  CAS  PubMed  Google Scholar 

  49. MHRA. SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum). 2019. Available at https://www.gov.uk/drug-safety-update/sglt2-inhibitors-reports-of-fournier-s-gangrene-necrotising-fasciitis-of-the-genitalia-or-perineum. (Accessed 15th Dec 2022)

  50. Napp Pharmaceutical Limited, 15 Nov 2013. Summary of Product Characteristics - Invokana (Canagliflozin). [Online]. Updated: 07 Dec 2021. Available at: https://www.medicines.org.uk/emc/product/8855/smpc (Accessed 15th Dec 2022).

  51. AstraZeneca, 12 Nov 2012. Summary of Product Characteristics - Forxiga (Dapagliflozin). (Online). Updated: 09 Dec 2022. Available at: https://www.medicines.org.uk/emc/product/7607/smpc (Accessed 15th Dec 2022).

  52. Boehringer Ingelheim, 22 May 2014. Summary of Product Characteristics - Jardiance (Empagliflozin). (Online). Updated 04 Nov 2022. Available at: https://www.medicines.org.uk/emc/product/5441/smpc. Accessed 15 Dec 2022.

  53. Merck Sharp & Dohme (UK) Limited, 01 Jan 2021. Summary of Product Characteristics – Steglatro (Ertugliflozin). (Online) Updated 13 April 2022. Available at: https://www.medicines.org.uk/emc/product/10099/smpc (Accessed 15th Dec 2022).

  54. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of Sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337–48.

    Article  CAS  PubMed  Google Scholar 

  55. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–22.

    Article  CAS  PubMed  Google Scholar 

  56. Ibrahim A, Ghaleb R, Mansour H, Hanafy A, Mahmoud NM, Abdelfatah Elsharef M, et al. Safety and efficacy of adding Dapagliflozin to furosemide in type 2 diabetic patients with decompensated heart failure and reduced ejection fraction. Front Cardiovasc Med. 2020;7:602251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). Circulation. 2022;146(4):289–98.

    Article  CAS  PubMed  Google Scholar 

  58. Tamaki S, Yamada T, Watanabe T, Morita T, Furukawa Y, Kawasaki M, et al. Effect of Empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure. Circ Heart Failure. 2021;14(3):e007048.

    Article  CAS  PubMed  Google Scholar 

  59. Thiele K, Rau M, Hartmann NUK, Möller M, Möllmann J, Jankowski J, et al. Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Failure. 2022;9(4):2233–8.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68): Clinicaltrials.gov; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04363697.

Download references

Acknowledgements

This document has been produced by the UK Kidney Association Clinical Practice Guideline Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease Working Group and has been externally reviewed by key stake holders according to the process described in the Clinical Practice Guidelines Development Policy Manual.

Endorsements

The National Institute for Health and Care Excellence (NICE) has accredited the process used by The UK Kidney Association to produce its Clinical Practice Guidelines. Accreditation is valid until December 2023. More information on accreditation can be viewed at www.nice.org.uk/accreditation.

Method used to arrive at a recommendation

The Recommendations for the first draft of this guideline resulted from a collective decision reached by informal discussion by the authors and, whenever necessary, with input from the Chair of the Clinical Practice Guidelines Committee. If no agreement had been reached on the appropriate grading of a Recommendation, a vote would have been held and the majority opinion carried. However this was not necessary for this guideline.

Funding

Not applicable.

Author information

Author notes

  1. William G. Herrington and Andrew H. Frankel contributed equally to this work.

Authors and Affiliations

  1. The Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK

    Alistair J. Roddick, Natalie Staplin & William G. Herrington

  2. Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

    Alistair J. Roddick & William G. Herrington

  3. Wales Kidney Research Unit, Cardiff University, Cardiff, UK

    Alexa Wonnacott & Donald Fraser

  4. Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK

    David Webb

  5. UKKA Patient Representative, Bristol, UK

    Angela Watt & Michael A. Watson

  6. Royal Free London NHS Foundation Trust, London, UK

    Alex Riding

  7. Kings College Hospital NHS Trust, London, UK

    Eirini Lioudaki

  8. John Walls Renal Unit, Glenfield Hospital, Leicester, UK

    Apexa Kuverji

  9. Doncaster Royal Infirmary, Doncaster, UK

    Mohsen El Kossi

  10. Primary Care Diabetes Society, Darlington, UK

    Patrick Holmes

  11. East Kent Hospitals University NHS Foundation Trust, Canterbury, UK

    Matt Holloway

  12. North East London Integrated Care Board, London, UK

    Chris Carvalho

  13. Clinical Effectiveness Group, Queen Mary University of London, London, UK

    Chris Carvalho

  14. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

    James O. Burton

  15. Hull University Teaching Hospitals NHS Trust and Hull York Medical School, Hull, UK

    Sunil Bhandari

  16. Imperial College Healthcare NHS Trust, London, UK

    Andrew H. Frankel

Authors
  1. Alistair J. Roddick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexa Wonnacott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Watt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael A. Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Natalie Staplin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alex Riding
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eirini Lioudaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Apexa Kuverji
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mohsen El Kossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Patrick Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Matt Holloway
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Donald Fraser
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Chris Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. James O. Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Sunil Bhandari
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. William G. Herrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Andrew H. Frankel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

WGH and AHF chaired the clinical guideline working group. All authors contributed to production of the clinical guidelines on which this manuscript is based. AJR, WGH and AHF wrote the manuscript with input from all authors. All authors reviewed and approved the final manuscript.

Corresponding author

Correspondence to Andrew H. Frankel.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

SB reports honoraria for lectures, presentations and speaker bureaus from Astra Zeneca. JOB reports a leadership position as chair of the UK Kidney Association Clinical Practice Guidelines Committee and reports honoraria for speaker bureaus from AstraZeneca, Boehringer-Ingelheim and NAPP. CC reports support from North East London Integrated Care Board, Clinical Effectiveness Group, Queen Mary University of London, and National Institute of Health Research, and reports a grant or contract from the NIHR School of Primary Care Research. MEK reports participation on advisory boards for GlaxoSmithKline and Astella. AHF reports an institutional grant from Boehringer-Ingelheim for participation in the EMPA-KIDNEY study, honoraria or personal fees from Boehringer-Ingelheim and AstraZeneca, support for attending meetings from AstraZeneca, and participation in advisory boards for Boehringer-Ingelheim and AstraZeneca. DF reports unpaid leadership roles with the American Society of Nephrology Education Committee, EuroPD management board, and the International Society of Peritoneal Dialysis Programme Committee. MH reports honoraria from AstraZeneca and UK Renal Pharmacy Group. PH reports a personal grant from Roche Diagnostics, honoraria or personal fees from AstraZeneca, NovoNordisk and Boehringer-Ingelheim, and participation in data safety monitoring board or advisory boards for Abbott, AstraZeneca, and Bayer. AJR, WGH and NS report institutional grant funding from Boehringer-Ingelheim and Eli Lilly. NS additionally reports institutional grant funding from NovoNordisk. WGH additionally reports funding from the UK Medical Research Council–Kidney Research UK Professor David Kerr Clinician Scientist Award. AWa reports honoraria and support for travel expenses from GlaxoSmithKline. DW reports honoraria from ABCD and Sanofi Aventis and reports participation in a data safety monitoring board or advisory board for the BARI 2 study. AWo reports honoraria from Bayer and AstraZeneca and participant in advisory board for Bayer. AK, EL, MAW, and AR have no competing interests to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roddick, A.J., Wonnacott, A., Webb, D. et al. UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE. BMC Nephrol 24, 310 (2023). https://doi.org/10.1186/s12882-023-03339-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12882-023-03339-3

Keywords

BMC Nephrology

ISSN: 1471-2369

Contact us